Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study.

Cancer medicine（2023）

引用 3|浏览47

暂无评分

摘要

The encouraging antitumor activity and favorable safety profile support the use of pemigatinib as a treatment in previously treated Chinese patients with cholangiocarcinoma and FGFR2 rearrangements.

查看译文

关键词

FGFR2 fusions or rearrangements,antitumor activity,cholangiocarcinoma,pemigatinib,phase II

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要